Disparity in public funding of systemic therapy for metastatic renal cell carcinoma within Canada

Authors Emily B. Jackson BC Cancer Sebastien J. Hotte McMaster University DOI: https://doi.org/10.5489/cuaj.7846 Keywords: Metastatic renal cell carcinoma, renal cell carcinoma, drug access, equity Abstract

Introduction: There have been significant advances in systemic therapies for metastatic renal cell carcinoma (mRCC). There are currently 11 drugs approved by Health Canada: sunitinib, sorafenib, pazopanib, axitinib, everolimus, temsirolimus, nivolumab, ipilimumab, cabozantinib, lenvatinib, and pembrolizumab. These novel medications have dramatically altered the prognosis and patient experience. Despite proven benefits and recommendations for funding of most of these drugs, public access has been uneven across Canadian provinces.

Methods: We describe the provincial differences and timelines in public funding for approved systemic therapies for mRCC in Canada. Drug funding data was collected from the pan-Canadian Oncology Drug Review (pCODR) database and provincial drug formularies. Missing information was obtained from provincial cancer center pharmacists or drug formulary managers. We compared these dates to data available through regulatory bodies in the U.S., Europe, and Australia.

Results: There have been significant differences in the dates of approval for public funding among the provinces, with lags spanning between two and 57 months. Funding approval was typically earlier in western provinces and those with denser populations, and most delayed in smaller, eastern provinces. Approval timelines in Canada were similar to those in the U.S., Europe, and Australia.

Conclusions: Most drugs approved for use in mRCC are publicly funded for specific patient populations across Canada; however, we illustrate considerable disparities in public funding implementation across the Canadian provinces. These funding lags may create inequities and differences in the patient experience across the Canadian healthcare system.

Downloads

Download data is not yet available.

How to Cite

Jackson, E. B., & Hotte, S. J. . (2022). Disparity in public funding of systemic therapy for metastatic renal cell carcinoma within Canada. Canadian Urological Association Journal, 16(11), E516–22. https://doi.org/10.5489/cuaj.7846

Issue Section

Original Research

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

Post the Article on any Web site Translate or authorize a translation of the Article Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party; That all individuals who have made a substantive contribution to the article are acknowledged; That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and That the Article does not libel or violate the privacy rights of any third party.

留言 (0)

沒有登入
gif